Department of Chemistry, University of Mumbai , Mumbai, India .
Nucleic Acid Ther. 2018 Aug;28(4):209-224. doi: 10.1089/nat.2017.0715. Epub 2018 Mar 27.
Since the evolutionary discovery of RNA interference and its utilization for gene knockdown in mammalian cell, a remarkable progress has been achieved in small interfering RNA (siRNA) therapeutics. siRNA is a promising tool, utilized as therapeutic agent against various diseases. Despite its significant potential benefits, safe, efficient, and target oriented delivery of siRNA is one of the major challenges in siRNA therapeutics. This review covers major achievements in clinical trials and targeted delivery of siRNAs using various targeting ligand-receptor pair. Local and systemically administered siRNA drug candidates at various phases in clinical trials are described in this review. This review also provides a deep insight in development of targeted delivery of siRNA. Various targeting ligand-siRNA pair with complexation and conjugation approaches are discussed in this review. This will help to achieve further optimization and development in targeted delivery of siRNAs to achieve higher gene silencing efficiency with lowest siRNA dose availability.
自 RNA 干扰的进化发现及其在哺乳动物细胞中的基因敲低应用以来,小干扰 RNA(siRNA)治疗学取得了显著进展。siRNA 是一种很有前途的工具,可用作针对各种疾病的治疗剂。尽管具有显著的潜在益处,但 siRNA 的安全、高效和靶向递送仍然是 siRNA 治疗学的主要挑战之一。本综述涵盖了利用各种靶向配体-受体对在临床试验中进行 siRNA 靶向递送的主要成就。本文综述了在临床试验的各个阶段局部和系统给予的 siRNA 候选药物。本综述还深入探讨了 siRNA 靶向递送的发展。本文讨论了各种具有复杂和共轭方法的靶向配体-siRNA 对,这将有助于进一步优化和开发 siRNA 的靶向递送来实现更高的基因沉默效率和最低的 siRNA 剂量可用性。